logo

For the Inventor, By the Inventor

Osaka, Japan

Kazumasa Yokoyama

This inventor holds 80 USPTO granted patents, primarily in Infusion Preparation (CPC class 514274). Top assignees: The Green Cross Corporation, Ishihara Sangyo Kaisha, Ltd., Taisho Pharmaceutical Co., Ltd.. Active years: 1976-2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazumasa Yokoyama. Retrieved from https://idiyas.com/inventor/kazumasa-yokoyama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 80

% Patents Active = 100.0

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 1,033(Granted Patents)

Forward Citations (Not Self Cited) = 982(Dec 10, 2025)


Inventors with similar research interests:


    Location History:

    • Suita, JA (1976 - 1977)
    • Suita, JP (1981)
    • Toyonaka, JP (1980 - 1993)
    • Hirakata, JP (1991 - 1997)
    • Osaka, JP (1987 - 2003)

    Company Filing History:

    goldMedal72 out of 264 
     
    The Green Cross Corporation
     patents
    silverMedal7 out of 394 
     
    Ishihara Sangyo Kaisha, Ltd.
     patents
    bronzeMedal3 out of 314 
     
    Taisho Pharmaceutical Co., Ltd.
     patents
    4. 3 out of 198 
     
    Yoshitomi Pharmaceutical Industries, Ltd.
     patents
    5. 1 out of 136 
     
    Kaken Pharmaceutical Company, Ltd.
     patents
    6. 1 out of 73 
     
    Mitsubishi Pharma Corporation
     patents
    7. 1 out of 324 
     
    Tanabe Seiyaku Company, Limited
     patents
    8. 1 out of 1 
     
    The Green Cross Company
     patent
    9. 1 out of 1 
     
    Yoshitomi Pharmaceutical
     patent
    where one patent can have more than one assignee

    Years Active: 1976-2003

    Loading Chart...
    Areas of Expertise:
    Recombinant Human Serum Albumin
    Infusion Liquids
    Pharmaceutical Composition
    Protein-Containing Composition
    Antithrombin-III
    Peptic Ulcer Agents
    Antiviral Agent
    Cycloalkane Derivatives
    Dihydropyridine Derivatives
    Perfluorochemicals
    Fatty Acid Supplemented Medium
    Indoleacetic Acid Derivatives
    80 patents (USPTO):Explore Patents
    1. 6617133 - Process for purifying recombinant human serum albumin (2003-09-09),
    2. 6475506 - Infusion preparation (2002-11-05),
    3. 6129925 - Container filled with infusion liquids and infusion preparation (2000-10-10),
    4. 5993863 - Alimentative infusion liquids for administration through peripheral vein (1999-11-30),
    5. 5986062 - Recombinant human serum albumin, process for producing the same and (1999-11-16),
    6. 5972367 - Infusion preparation (1999-10-26),
    7. 5962649 - Process for purifying recombinant human serum albumin (1999-10-05),
    8. 5770233 - Container filled with infusion liquids and infusion preparation (1998-06-23),
    9. 5728681 - Infusion preparation and two compartment container containing the (1998-03-17),
    10. 5674527 - Infusion preparation comprising phospholipid (1997-10-07),
    11. 5643792 - Mutant strain of Pichia pastoris which utilizes methanol in the presence (1997-07-01),
    12. 5626880 - Infusion preparation (1997-05-06),
    13. 5610169 - Pharmaceutical Composition containing slightly water-soluble drug (1997-03-11),
    14. 5589516 - Liquid preparation of antithrombin-III and stabilizing method therefor (1996-12-31),
    15. 5521287 - Recombinant human serum albumin, process for producing the same and (1996-05-28),

    Title: Kazumasa Yokoyama: Innovator in Nutritional Science and Biopharmaceuticals

    Introduction

    Kazumasa Yokoyama, based in Osaka, Japan, is a prominent inventor known for his extensive contributions to the fields of nutritional science and biopharmaceuticals. With an impressive portfolio of 80 patents, Yokoyama has significantly impacted the development of novel solutions for enhancing human health and well-being.

    Latest Patents

    Yokoyama's latest inventions include a process for purifying recombinant human serum albumin (rHSA). This patented process involves heating a culture medium containing rHSA and its producing host cells, followed by feeding the heated solution into a fluidized bed with adsorbent particles. This innovation allows for the effective recovery of the adsorbed fraction containing rHSA, which is crucial for various medical applications. Additionally, Yokoyama has developed an infusion preparation designed for nutrient supply, consisting of sugars, amino acids, electrolytes, and a fat emulsion. This formulation boasts an exceptional shelf life and stability, preventing precipitation and denaturation of ingredients. Notably, the infusion liquid can be easily prepared aseptically by removing a separation means within the container, ensuring convenience in medical settings.

    Career Highlights

    Throughout his career, Kazumasa Yokoyama has worked with reputable companies, including the Green Cross Corporation and Ishihara Sangyo Kaisha, Ltd. His role in these organizations has allowed him to refine his expertise in the biopharmaceutical industry and contribute to innovative solutions that address healthcare challenges.

    Collaborations

    Yokoyama's journey as an inventor has seen fruitful collaborations with notable colleagues, including Chikara Fukaya and Tadakazu Suyama. These partnerships have played a vital role in fostering a dynamic environment for research and development, facilitating the creation of groundbreaking inventions that benefit society.

    Conclusion

    Kazumasa Yokoyama's dedication to innovation and his remarkable achievements in the realm of patents underscore his position as a leading figure in nutritional science and biopharmaceuticals. His inventions not only demonstrate his technical expertise but also his commitment to improving health outcomes through effective and safe solutions.

    Profile summary based on public USPTO records.
    Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
    Loading…